Cipher Pharmaceuticals (TSE:CPH) Shares Cross Below 50 Day Moving Average – What’s Next?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s share price passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$13.99 and traded as low as C$13.33. Cipher Pharmaceuticals shares last traded at C$13.39, with a volume of 3,809 shares.

Cipher Pharmaceuticals Stock Performance

The company has a market cap of C$340.31 million, a price-to-earnings ratio of 11.96 and a beta of 1.26. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.59 and a quick ratio of 2.67. The stock has a 50-day moving average price of C$13.99 and a 200 day moving average price of C$16.03.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported C$0.21 earnings per share (EPS) for the quarter. The business had revenue of C$17.14 million during the quarter. Cipher Pharmaceuticals had a return on equity of 22.74% and a net margin of 58.81%. As a group, analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.29 EPS for the current fiscal year.

Insider Activity

In other Cipher Pharmaceuticals news, Director Craig Mull acquired 20,000 shares of the stock in a transaction dated Friday, September 18th. The shares were bought at an average cost of C$14.16 per share, for a total transaction of C$283,200.00. Following the completion of the acquisition, the director directly owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This trade represents a 2.02% increase in their ownership of the stock. 42.00% of the stock is owned by company insiders.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.